Method for treating a sphincter

Information

  • Patent Grant
  • 6712814
  • Patent Number
    6,712,814
  • Date Filed
    Tuesday, October 9, 2001
    23 years ago
  • Date Issued
    Tuesday, March 30, 2004
    20 years ago
Abstract
A method of treating a sphincter that provides an expandable basket structure with a first energy delivery device. The basket structure is introduced in a sphincter. The first energy delivery device is advanced from the basket structure into an interior of the sphincter. Sufficient energy is delivered from the first energy delivery device to create a desired tissue effect in the sphincter. Thereafter, the basket structure is removed from the sphincter.
Description




BACKGROUND OF THE INVENTION




1. Field of the Invention




This invention relates generally to a method for the treatment of sphincters, and more specifically to a method that treats esophageal sphincters.




2. Description of Related Art




Gastroesophageal reflux disease (GERD) is a common gastroesophageal disorder in which the stomach contents are ejected into the lower esophagus due to a dysfunction of the lower esophageal sphincter (LES). These contents are highly acidic and potentially injurious to the esophagus resulting in a number of possible complications of varying medical severity. The reported incidence of GERD in the U.S. is as high as 10% of the population (Castell D O; Johnston B T:


Gastroesophageal Reflux Disease: Current Strategies For Patient Management


. Arch Fam Med, 5(4):221-7: (1996 April)).




Acute symptoms of GERD include heartburn, pulmonary disorders and chest pain. On a chronic basis, GERD subjects the esophagus to ulcer formation, or esophagitis and may result in more severe complications including esophageal obstruction, significant blood loss and perforation of the esophagus. Severe esophageal ulcerations occur in 20-30% of patients over age 65. Moreover, GERD causes adenocarcinoma, or cancer of the esophagus, which is increasing in incidence faster than any other cancer (Reynolds J C:


Influence Of Pathophysiology, Severity, And Cost On The Medical Management Of Gastroesophageal Reflux Disease


. Am J Health Syst Pharm, 53(22 Suppl 3):S5-12 (Nov. 15, 1996)).




One of the possible causes of GERD may be aberrant electrical signals in the LES or cardia of the stomach. Such signals may cause a higher than normal frequency of relaxations of the LES allowing acidic stomach contents to be repeatedly ejected into the esophagus and cause the complications described above. Research has shown that unnatural electrical signals in the stomach and intestine can cause reflux events in those organs (Kelly K A, et al:


Duodenal


-


gastric Reflux and Slowed Gastric Emptying by Electrical Pacing of the Canine Duodenal Pacesetter Potential


. Gastroenterology. 1977 Mar; 72(3): 429-433). In particular, medical research has found that sites of aberrant electrical activity or electrical foci may be responsible for those signals (Karlstrom L H, et al.:


Ectopic Jejunal Pacemakers and Enterogastric Reflux after Roux Gastrectomy: Effect Intestinal Pacing


. Surgery. 1989 September; 106(3): 486-495). Similar aberrant electrical sites in the heart which cause contractions of the heart muscle to take on life threatening patterns or dysrhythmias can be identified and treated using mapping and ablation devices as described in U.S. Pat. No. 5,509,419. However. there is no current device or associated medical procedure available for the electrical mapping and treatment of aberrant electrical sites in the LES and stomach as a means for treating GERD.




Current drug therapy for GERD includes histamine receptor blockers which reduce stomach acid secretion and other drugs which may completely block stomach acid. However, while pharmacologic agents may provide short term relief, they do not address the underlying cause of LES dysfunction.




Invasive procedures requiring percutaneous introduction of instrumentation into the abdomen exist for the surgical correction of GERD. One such procedure, Nissen fundoplication, involves constructing a new “valve” to support the LES by wrapping the gastric fundus around the lower esophagus. Although the operation has a high rate of success, it is an open abdominal procedure with the usual risks of abdominal surgery including: postoperative infection, herniation at the operative site, internal hemorrhage and perforation of the esophagus or of the cardia. In fact, a recent 10 year, 344 patient study reported the morbidity rate for this procedure to be 17% and mortality 1% (Urschel, J D:


Complications Of Antireflux Surgery


, Am J Surg 166(1): 68-70; (1993 July)). This rate of complication drives up both the medical cost and convalescence period for the procedure and may exclude portions of certain patient populations (e.g., the elderly and immuno-compromised).




Efforts to perform Nissen fundoplication by less invasive techniques have resulted in the development of laparoscopic Nissen fundoplication. Laparoscopic Nissen fundoplication, reported by Dallemagne et al.


Surgical Laparoscopy and Endoscopy


, Vol. 1, No. 3. (1991), pp. 138-43 and by Hindler et al.


Surgical Laparoscopy and Endoscopy


, Vol. 2. No. 3. (1992), pp. 265-272, involves essentially the same steps as Nissen fundoplication with the exception that surgical manipulation is performed through a plurality of surgical cannula introduced using trocars inserted at various positions in the abdomen.




Another attempt to perform fundoplication by a less invasive technique is reported in U.S. Pat. No. 5,088,979. In this procedure an invagination device containing a plurality of needles is inserted transorally into the esophagus with the needles in a retracted position. The needles are extended to engage the esophagus and fold the attached esophagus beyond the gastroesophageal junction. A remotely operated stapling device, introduced percutaneously through an operating channel in the stomach wall, is actuated to fasten the invaginated gastroesophageal junction to the surrounding involuted stomach wall.




Yet another attempt to perform fundoplication by a less invasive technique is reported in U.S. Pat. No. 5,676,674. In this procedure, invagination is done by a jaw-like device and fastening of the invaginated gastroesophageal junction to the fundus of the stomach is done via a transoral approach using a remotely operated fastening device, eliminating the need for an abdominal incision. However, this procedure is still traumatic to the LES and presents the postoperative risks of gastroesophageal leaks, infection and foreign body reaction, the latter two sequela resulting when foreign materials such as surgical staples are implanted in the body.




While the methods reported above are less invasive than an open Nissen fundoplication, some still involve making an incision into the abdomen and hence the increased morbidity and mortality risks and convalescence period associated with abdominal surgery. Others incur the increased risk of infection associated with placing foreign materials into the body. All involve trauma to the LES and the risk of leaks developing at the newly created gastroesophageal junction.




Besides the LES, there are other sphincters in the body which if not functionally properly can cause disease states or otherwise adversely affect the lifestyle of the patient. Reduced muscle tone or otherwise aberrant relaxation of sphincters can result in a laxity of tightness disease states including, but not limited to, urinary incontinence.




There is a need to provide a method to treat a sphincter and reduce a frequency of sphincter relaxation. Another need exists for a method to create controlled cell necrosis in a sphincter tissue underlying a sphincter mucosal layer. Yet another need exists for a method to create cell necrosis in a sphincter and minimize injury to a mucosal layer of the sphincter. There is another need for a method to controllably produce a lesion in a sphincter without creating a permanent impairment of the sphincter's ability to achieve a physiologically normal state of closure. Still a further need exists for a method to create a tightening of a sphincter without permanently damaging anatomical structures near the sphincter. There is still another need for a method to create cell necrosis in a lower esophageal sphincter to reduce a frequency of reflux of stomach contents into an esophagus.




SUMMARY OF THE INVENTION




Accordingly, an object of the present invention is to provide a method to treat a sphincter and reduce a frequency of sphincter relaxation.




Another object of the invention is to provide a method to create controlled cell necrosis in a sphincter tissue underlying a sphincter mucosal layer.




Yet another object of the invention is to provide a method to create cell necrosis in a sphincter and minimize injury to a mucosal layer of the sphincter.




A further object of the invention is to provide a method to controllably produce a lesion in a sphincter without creating a permanent impairment of the sphincter's ability to achieve a physiologically normal state of closure.




Still another object of the invention is to provide a method to create a tightening of a sphincter without permanently damaging anatomical structures near the sphincter.




Another object of the invention is to provide a method to create cell necrosis in a lower esophageal sphincter to reduce a frequency of reflux of stomach contents into an esophagus.




Yet another object of the invention is to provide a method to reduce the frequency and severity of gastroesophageal reflux events.




These and other objects of the invention are provided in a method of treating a sphincter that provides an expandable basket structure with a first energy delivery device. The basket structure is introduced in a sphincter. The first energy delivery device is advanced from the basket structure into an interior of the sphincter. Sufficient energy is delivered from the first energy delivery device to create a desired tissue effect in the sphincter. Thereafter, the basket structure is removed from the sphincter.











BRIEF DESCRIPTION OF THE DRAWINGS





FIG. 1

is an illustrated lateral view of the upper GI tract including the esophagus and lower esophageal sphincter and the positioning of a sphincter treatment apparatus in the lower esophageal sphincter.





FIG. 2

is a lateral view of a treatment apparatus, useful with the method of the present invention, illustrating an energy delivery device, power supply and expansion device in an expanded and contracted state.





FIG. 3

depicts a lateral view of an apparatus, useful with the method of the present invention, that illustrates components on the flexible shaft including a proximal fitting, connections and proximal and distal shaft segments.





FIG. 4

illustrates a lateral view of a basket assembly that can be used in the method of the present invention.





FIG. 5A

is a lateral view of the basket assembly that illustrates the range of camber in the basket assembly.





FIG. 5B

is a perspective view illustrating a balloon coupled to the basket assembly.





FIG. 6A

is a lateral view of the junction between the basket arms and the shaft illustrating the pathway used for advancement of the movable wire or the delivery of fluids.





FIG. 6B

is a frontal view of a basket arm in an alternative embodiment of an apparatus, useful with the method of the present invention, illustrating a track in the arm used to advance the movable wire.





FIG. 7

is a cross-sectional view of a section of the basket arm illustrating stepped and tapered sections in basket arm apertures.





FIG. 8

is a lateral view of the basket assembly illustrating the placement of the radial supporting member.





FIG. 9A

is a lateral view of the sphincter treatment apparatus, useful with the method of the present invention, illustrating the mechanism used in one embodiment to increase the camber of the basket assembly.





FIG. 9B

is a similar view to


9


A showing the basket assembly in an increased state of camber.





FIG. 10

is a lateral view of a sphincter treatment apparatus, useful with the method of the present invention, illustrating the deflection mechanism.





FIG. 11

is a lateral view illustrating the use of electrolytic solution to create an enhanced RF electrode.





FIG. 12

is a lateral view of the basket assembly illustrating the use of needle electrodes.





FIG. 13

is a lateral view illustrating the use of an insulation segment on the needle electrode to protect an area of tissue from RF energy.





FIG. 14

is a lateral view illustrating the placement of needle electrodes into the sphincter wall by expansion of the basket assembly.





FIG. 15

is a lateral view illustrating placement of needle electrodes into the sphincter wall by advancement of an electrode delivery member out of apertures in the basket arms.





FIG. 16

is a cross sectional view illustrating the configuration of a basket arm aperture used to select and maintain a penetration angle of the needle electrode into the sphincter wall.





FIG. 17

is a lateral view illustrating placement of needle electrodes into the sphincter wall by advancement of an electrode delivery member directly out of the distal end of the shaft.





FIG. 18A

is a lateral view illustrating a radial distribution of electrodes on the expansion device useful with the method of the present invention.





FIG. 18B

is a lateral view illustrating a longitudinal distribution of electrodes on the expansion device useful with the method of the present invention.





FIG. 18C

is a lateral view illustrating a spiral distribution of electrodes on the expansion device useful with the method of the present invention.





FIG. 19

is a flow chart illustrating the sphincter treatment method of the current invention.





FIG. 20

is a lateral view of sphincter smooth muscle tissue illustrating electromagnetic foci and pathways for the origination and conduction of aberrant electrical signals in the smooth muscle of the lower esophageal sphincter or other tissue.





FIG. 21

is a lateral view of a sphincter wall illustrating the infiltration of tissue healing cells into a lesion in the smooth tissue of a sphincter following treatment with the sphincter treatment apparatus useful with the method of the present invention.





FIG. 22

is a view similar to that of

FIG. 21

illustrating shrinkage of the lesion site caused by cell infiltration.





FIG. 23

is a lateral view of the esophageal wall illustrating the preferred placement of lesions in the smooth muscle layer of a esophageal sphincter.





FIG. 24

is a lateral view illustrating the ultrasound transducer, ultrasound lens and power source of an embodiment of an apparatus useful with the method of the present invention.





FIGS. 25A-D

are lateral views of the sphincter wall illustrating various patterns of lesions created by an apparatus in one method of the present invention.





FIG. 26

is a lateral view of the sphincter wall illustrating the delivery of cooling fluid to the electrode-tissue interface and the creation of cooling zones.





FIG. 27

depicts the flow path, fluid connections and control unit employed to deliver fluid to the electrode-tissue interface.





FIG. 28

depicts the flow path, fluid connections and control unit employed to deliver fluid to the RF electrodes.





FIG. 29

is an enlarged lateral view illustrating the placement of sensors on the expansion device or basket assembly.





FIG. 30

depicts a block diagram of the feed back control system that can be used with the sphincter treatment apparatus useful with the method of the present invention.





FIG. 31

depicts a block diagram of an analog amplifier, analog multiplexer and microprocessor used with the feedback control system of FIG.


30


.





FIG. 32

depicts a block diagram of the operations performed in the feedback control system depicted in FIG.


30


.











DETAILED DESCRIPTION




Referring now to

FIGS. 1 and 2

, one embodiment of sphincter treatment apparatus


10


that is used to deliver energy to a treatment site


12


to produce lesions


14


in a sphincter


16


, such as the lower esophageal sphincter (LES), comprises a flexible elongate shaft


18


, also called shaft


18


, coupled to a expansion device


20


, in turn coupled with one or more energy delivery devices


22


. Energy delivery devices


22


are configured to be coupled to a power source


24


. The expansion device


20


is configured to be positionable in a sphincter


16


such as the LES or adjacent anatomical structure, such as the cardia of the stomach. Expansion device


20


is further configured to facilitate the positioning of energy delivery devices


22


to a selectable depth in a sphincter wall


26


or adjoining anatomical structure. Expansion device


20


has a central longitudinal axis


28


and is moveable between contracted and expanded positions substantially there along. This can be accomplished by a ratchet mechanism as is known to those skilled in the art. At least portions of sphincter treatment apparatus


10


may be sufficiently radiopaque in order to be visible under fluoroscopy and/or sufficiently echogenic to be visible under ultrasonography. Also as will be discussed herein, sphincter treatment apparatus


10


can include visualization capability including, but not limited to, a viewing scope, an expanded eyepiece, fiber optics, video imaging and the like.




Referring to

FIG. 2

, shaft


18


is configured to be coupled to expansion device


20


and has sufficient length to position expansion device


20


in the LES and/or stomach using a transoral approach. Typical lengths for shaft


18


include, but are not limited to, a range of 40-180 cms. In various embodiments, shaft


18


is flexible, articulated and steerable and can contain fiber optics (including illumination and imaging fibers, fluid and gas paths, and sensor and electronic cabling. In one embodiment, shaft


18


can be a multi-lumen catheter, as is well known to those skilled in the art. In another embodiment, an introducing member


21


, also called an introducer, is used to introduce sphincter treatment apparatus


10


into the LES. Introducer


21


can also function as a sheath for expansion device


20


to keep it in a nondeployed or contracted state during introduction into the LES. In various embodiments, introducer


21


is flexible, articulated and steerable and contains a continuous lumen of sufficient diameter to allow the advancement of sphincter treatment apparatus


10


. Typical diameters for introducer


21


include 0.1 to 2 inches, while typical length include 40-180 cms. Suitable materials for introducer


21


include coil-reinforced plastic tubing as is well known to those skilled in the art.




Referring now to

FIG. 3

, the flexible elongate shaft


18


is circular in cross section and has proximal and distal extremities (also called ends)


30


and


32


. Shaft


18


may also be coupled at its proximal end


32


to a proximal fitting


34


, also called a handle, used by the physician to manipulate sphincter treatment apparatus


10


to reach treatment site


12


. Shaft


18


may have one or more lumens


36


, that extend the full length of shaft


18


, or part way from shaft proximal end


30


to shaft distal end


32


. Lumens


36


may be used as paths for catheters, guide wires, pull wires, insulated wires and cabling, fluid and optical fibers. Lumens


36


are connected to and/or accessed by connections


38


on or adjacent to proximal fitting


34


. Connections


38


can include luer-lock, lemo connector, swage and other mechanical varieties well known to those skilled in the art. Connections


38


can also include optical/video connections which allow optical and electronic coupling of optical fibers and/or viewing scopes to illuminating sources, eye pieces and video monitors. In various embodiments, shaft


18


may stop at the proximal extremity


40


of expansion device


20


or extend to, or past, the distal extremity


42


of expansion device


20


. Suitable materials for shaft


18


include, but are not limited to, polyethylenes, polyurethanes and other medical plastics known to those skilled in the art.




Referring now to

FIG. 4

, in one embodiment of the present invention, expansion device


20


comprises one or more elongated arms


44


that are joined at their proximal ends


46


and distal ends


48


to form a basket assembly


50


. Proximal arm end


46


is attached to a supporting structure, which can be the distal end


32


of shaft


18


or a proximal cap


51


. Likewise, distal arm end


48


is also attached to a supporting structure which can be a basket cap


52


or shaft


18


. Attached arms


44


may form a variety of geometric shapes including, but not limited to, curved, rectangular, trapezoidal and triangular. Arms


44


can have a variety of cross sectional geometries including, but not limited to circular, rectangular and crescent-shaped. Also, arms


44


are of a sufficient number (two or more), and have sufficient spring force (0.01 to 0.5 lbs. force) so as to collectively exert adequate force on sphincter wall


26


to sufficiently open and efface the folds of sphincter


16


to allow treatment with sphincter treatment apparatus


10


, while preventing herniation of sphincter wall


26


into the spaces


53


between arms


44


. Suitable materials for arms


44


include, but are not limited to, spring steel, stainless steel, superelastic shape memory metals such as nitinol or wire reinforced plastic tubing as is well known to those skilled in the art.




Referring to

FIG. 5A

, arms


44


can have an outwardly bowed shaped memory for expanding the basket assembly into engagement with sphincter wall


26


with the amount of bowing, or camber


54


being selectable from a range 0 to 2 inches from longitudinal axis


28


of basket assembly


50


. For the case of a curve-shaped arm


44


′, expanded arms


44


′ are circumferentially and symmetrically spaced-apart.




In another embodiment shown in

FIG. 5B

, an expandable member


55


. which can be a balloon, is coupled to an interior or exterior of basket assembly


50


. Balloon


55


is also coupled to and inflated by lumen


36


using gas or liquid. In various other embodiments (not shown), arms


44


may be asymmetrically spaced and/or distributed on an arc less than 360°. Also, arms


44


may be preshaped at time of manufacture or shaped by the physician.




Referring now to

FIG. 6A

, arms


44


may also be solid or hollow with a continuous lumen


58


that may be coupled with shaft lumens


36


. These coupled lumens provide a path for the delivery of a fluid or electrode delivery member


60


from shaft


18


to any point on basket assembly


50


. In various embodiments electrode delivery member


60


can be an insulated wire, an insulated guide wire, a plastic-coated stainless steel hypotube with internal wiring or a plastic catheter with internal wiring, all of which are known to those skilled in the art. As shown in

FIG. 6B

, arms


44


may also have a partially open channel


62


, also called a track


62


, that functions as a guide track for electrode delivery member


60


. Referring back to

FIG. 6A

, arms


44


may have one or more apertures


64


at any point along their length that permit the controlled placement of energy delivery devices


22


at or into sphincter wall


26


. Referring now to

FIG. 7

, apertures


64


may have tapered sections


66


or stepped sections


68


in all or part of their length, that are used to control the penetration depth of energy delivery devices


22


into sphincter wall


26


. Referring back to

FIG. 6A

, apertures


64


in combination with arm lumens


58


and shaft lumens


36


may be used for the delivery of cooling solution


70


or electrolytic solution


72


to treatment site


12


as described herein. Additionally, arms


44


can also carry a plurality of longitudinally spaced apart radiopaque and or echogenic markers or traces, not shown in the drawings, formed of suitable materials to permit viewing of basket assembly


50


via fluoroscopy or ultrasonography. Suitable radiopaque materials include platinum or gold, while suitable echogenic materials include gas filled micro-particles as described in U.S. Pat. Nos. 5,688,490 and 5,205,287. Arms


44


may also be color-coded to facilitate their identification via visual medical imaging methods and equipment, such as endoscopic methods, which are well known to those skilled in the art.




In another embodiment of the present invention, a supporting member


74


is attached to two or more arms


44


. Supporting member


74


, also called a strut, can be attached to arms


44


along a circumference of basket assembly


50


as shown in FIG.


8


. Apertures


64


can extend through radial supporting member


74


in one or more places. Radial supporting member


74


serves the following functions: i) facilitates opening and effacement of the folds of sphincter


16


, ii) enhances contact of Apertures


64


with sphincter wall


26


; and, iii) reduces or prevents the tendency of arms


44


to bunch up. The cross sectional geometry of radial supporting member


74


can be rectangular or circular, though it will be appreciated that other geometries are equally suitable.




In one embodiment shown in

FIG. 9

, arms


44


are attached to basket cap


52


that in turn, moves freely over shaft


18


, but is stopped distally by shaft cap


78


. One or more pull wires


80


are attached to basket cap


52


and also to a movable fitting


82


in proximal fitting


34


of sphincter treatment apparatus


10


. When pull wire


80


is pulled back by movable fitting


82


, the camber


54


of basket assembly


50


increases to


54


′, increasing the force and the amount of contact applied by basket assembly


50


to sphincter wall


26


or an adjoining structure. Basket assembly


50


can also be deflected from side to side using deflection mechanism


80


. This allows the physician to remotely point and steer the basket assembly within the body. In one embodiment shown in

FIG. 10

, deflection mechanism


84


includes a second pull wire


80


′ attached to shaft cap


78


and also to a movable slide


86


integral to proximal fitting


34


.




Turning now to a discussion of energy delivery, suitable power sources


24


and energy delivery devices


22


that can be employed in one or more embodiments of the invention include: (i) a radio-frequency (RF) source coupled to an RF electrode, (ii) a coherent source of light coupled to an optical fiber, (iii) an incoherent light source coupled to an optical fiber, (iv) a heated fluid coupled to a catheter with a closed channel configured to receive the heated fluid, (v) a heated fluid coupled to a catheter with an open channel configured to receive the heated fluid, (vi) a cooled fluid coupled to a catheter with a closed channel configured to receive the cooled fluid, (vii) a cooled fluid coupled to a catheter with an open channel configured to receive the cooled fluid, (viii) a cryogenic fluid, (ix) a resistive heating source, (x) a microwave source providing energy from 915 MHz to 2.45 GHz and coupled to a microwave antenna, (xi) an ultrasound power source coupled to an ultrasound emitter, wherein the ultrasound power source produces energy in the range of 300 KHZ to 3 GHz, or (xii) a microwave source. For ease of discussion for the remainder of this application, the power source utilized is an RF source and energy delivery device


22


is one or more RF electrodes


88


, also described as electrodes


88


. However, all of the other herein mentioned power sources and energy delivery devices are equally applicable to sphincter treatment apparatus


10


.




For the case of RF energy, RF electrode


88


may operated in either bipolar or monopolar mode with a ground pad electrode. In a monopolar mode of delivering RF energy, a single electrode


88


is used in combination with an indifferent electrode patch that is applied to the body to form the other electrical contact and complete an electrical circuit. Bipolar operation is possible when two or more electrodes


88


are used. Multiple electrodes


88


may be used. These electrodes may be cooled as described herein. Electrodes


88


can be attached to electrode delivery member


60


by the use of soldering methods which are well known to those skilled in the art. Suitable solders include Megabond Solder supplied by the Megatrode Corporation (Milwaukee, Wis.).




Suitable electrolytic solutions


72


include saline, solutions of calcium salts. potassium salts, and the like. Electrolytic solutions


72


enhance the electrical conductivity of the targeted tissue at the treatment site


12


. When a highly conductive fluid such as electrolytic solution


72


is infused into tissue the electrical resistance of the infused tissue is reduced, in turn, increasing the electrical conductivity of the infused tissue. As a result, there will be little tendency for tissue surrounding electrode


88


to desiccate (a condition described herein that increases the electrical resistance of tissue) resulting in a large increase in the capacity of the tissue to carry RF energy. Referring to

FIG. 11

, a zone of tissue which has been heavily infused with a concentrated electrolytic solution


72


can become so conductive as to actually act as an enhanced electrode


88


′. The effect of enhanced electrode


88


′ is to increase the amount of current that can be conducted to the treatment site


12


, making it possible to heat a much greater volume of tissue in a given time period.




Also when the power source is RF, power source


24


, which will now be referred to as RF power source


24


, may have multiple channels, delivering separately modulated power to each electrode


88


. This reduces preferential heating that occurs when more energy is delivered to a zone of greater conductivity and less heating occurs around electrodes


88


which are placed into less conductive tissue. If the level of tissue hydration or the blood infusion rate in the tissue is uniform, a single channel RF power source


24


may be used to provide power for generation of lesions


14


relatively uniform in size.




Electrodes


88


can have a variety of shapes and sizes. Possible shapes include, but are not limited to, circular, rectangular, conical and pyramidal. Electrode surfaces can be smooth or textured and concave or convex. The conductive surface area of electrode


88


can range from 0.1 mm


2


to 100 cm


2


. It will be appreciated that other geometries and surface areas may be equally suitable. In one embodiment, electrodes


88


can be in the shape of needles and of sufficient sharpness and length to penetrate into the smooth muscle of the esophageal wall, sphincter


16


or other anatomical structure. In this embodiment shown in

FIGS. 12 and 13

, needle electrodes


90


are attached to arms


44


and have an insulating layer


92


, covering an insulated segment


94


except for an exposed segment


95


. For purposes of this disclosure, an insulator or insulation layer is a barrier to either thermal, RF or electrical energy flow. Insulated segment


94


is of sufficient length to extend into sphincter wall


26


and minimize the transmission of RF energy to a protected site


97


near or adjacent to insulated segment


94


(see FIG.


13


). Typical lengths for insulated segment


94


include, but are not limited to, 1-4 mms. Suitable materials for needle electrodes


90


include, but are not limited to, 304 stainless steel and other stainless steels known to those skilled in the art. Suitable materials for insulating layer


92


include, but are not limited to, polyimides and polyamides.




During introduction of sphincter treatment apparatus


10


, basket assembly


50


is in a contracted state. Once sphincter treatment apparatus


10


is properly positioned at the treatment site


12


, needle electrodes


90


are deployed by expansion of basket assembly


50


, resulting in the protrusion of needle electrodes


90


into the smooth muscle tissue of sphincter wall


26


(refer to

FIG. 14

). The depth of needle penetration is selectable from a range of 0.5 to 5 mms and is accomplished by indexing movable fitting


82


so as to change the camber


54


of arm


44


in fixed increments that can be selectable in a range from 0.1 to 4 mms. Needle electrodes


90


are coupled to power source


24


via insulated wire


60


.




In another embodiment of sphincter treatment apparatus


10


shown in

FIG. 15

, needle electrodes


90


are advanced out of apertures


64


in basket arms


44


into the smooth muscle of the esophageal wall or other sphincter


16


. In this case, needle electrodes


90


are coupled to RF power source


24


by electrode delivery member


60


. In this embodiment, the depth of needle penetration is selectable via means of stepped sections


66


or tapered sections


68


located in apertures


64


. Referring to

FIG. 16

, apertures


64


and needle electrodes


90


are configured such that the penetration angle


96


(also called an emergence angle


96


) of needle electrode


90


into sphincter wall


26


remains sufficiently constant during the time needle electrode


90


is being inserted into sphincter wall


26


, such that there is no tearing or unnecessary trauma to sphincter wall tissue. This is facilitated by the selection of the following parameters and criteria: i) the emergence angle


96


of apertures


64


which can vary from 1 to 90°, ii) the arc radius


98


of the curved section


100


of aperture


64


which can vary from 0.001 to 2 inch, iii) the amount of clearance between the aperture inner diameter


102


and the needle electrode outside diameter


104


which can very between 0.001″ and 0.1″; and, iv) use of a lubricous coating on electrode delivery member


60


such as a Teflon ® or other coatings well known to those skilled in the art. Also in this embodiment, insulated segment


94


can be in the form of an sleeve that may be adjustably positioned at the exterior of electrode


90


.




In another alternative embodiment shown in

FIG. 17

, electrode delivery member


60


with attached needle electrodes


90


, can exit from lumen


36


at distal shaft end


32


and be positioned into contact with sphincter wall


26


. This process may be facilitated by use of a hollow guiding member


101


, known to those skilled in the art as a guiding catheter, through which electrode delivery member


60


is advanced. Guiding catheter


101


may also include stepped sections


66


or tapered sections


68


at it distal end to control the depth of penetration of needle electrode


90


into sphincter wall


26


.




RF energy flowing through tissue causes heating of the tissue due to absorption of the RF energy by the tissue and ohmic heating due to electrical resistance of the tissue. This heating can cause injury to the affected cells and can be substantial enough to cause cell death, a phenomenon also known as cell necrosis. For ease of discussion for the remainder of this application, cell injury will include all cellular effects resulting from the delivery of energy from electrode


88


up to, and including, cell necrosis. Cell injury can be accomplished as a relatively simple medical procedure with local anesthesia. In one embodiment, cell injury proceeds to a depth of approximately 1-4 mms from the surface of the mucosal layer of sphincter


16


or that of an adjoining anatomical structure.




Referring now to

FIGS. 18A

,


18


B and


18


C, electrodes


88


and/or apertures


64


may be distributed in a variety of patterns along expansion device


20


or basket assembly


50


in order to produce a desired placement and pattern of lesions


14


. Typical electrode and aperture distribution patterns include, but are not limited to, a radial distribution


105


(refer to

FIG. 18A

) or a longitudinal distribution


106


(refer to FIG.


18


B). It will be appreciated that other patterns and geometries for electrode and aperture placement, such as a spiral distribution


108


(refer to

FIG. 18C

) may also be suitable. These electrodes may be cooled as described hereafter.





FIG. 19

is a flow chart illustrating one embodiment of the procedure for using sphincter treatment apparatus


10


. In this embodiment, sphincter treatment apparatus


10


is first introduced into the esophagus under local anesthesia. Sphincter treatment apparatus


10


can be introduced into the esophagus by itself or through a lumen in an endoscope (not shown), such as disclosed in U.S. Pat. Nos. 5,448,990 and 5,275,608, incorporated herein by reference, or similar esophageal access device known to those skilled in the art. Basket assembly


50


is expanded as described herein. This serves to temporarily dilate the LES or sufficiently to efface a portion of or all of the folds of the LES. In an alternative embodiment, esophageal dilation and subsequent LES fold effacement can be accomplished by insufflation of the esophagus (a known technique) using gas introduced into the esophagus through shaft lumen


36


, or an endoscope or similar esophageal access device as described above. Once treatment is completed, basket assembly


50


is returned to its predeployed or contracted state and sphincter treatment apparatus


10


is withdrawn from the esophagus. This results in the LES returning to approximately its pretreatment state and diameter. It will be appreciated that the above procedure is applicable in whole or part to the treatment of other sphincters in the body.




The diagnostic phase of the procedure can be performed using a variety of diagnostic methods, including, but not limited to, the following: (i) visualization of the interior surface of the esophagus via an endoscope or other viewing apparatus inserted into the esophagus, (ii) visualization of the interior morphology of the esophageal wall using ultrasonography to establish a baseline for the tissue to be treated, (iii) impedance measurement to determine the electrical conductivity between the esophageal mucosal layers and sphincter treatment apparatus


10


and (iv) measurement and surface mapping of the electropotential of the LES during varying time periods which may include such events as depolarization, contraction and repolarization of LES smooth muscle tissue. This latter technique is done to determine target treatment sites


12


in the LES or adjoining anatomical structures that are acting as foci


107


or pathways


109


for abnormal or inappropriate polarization and relaxation of the smooth muscle of the LES (Refer to FIG.


20


).




In the treatment phase of the procedure, the delivery of energy to treatment site


12


can be conducted under feedback control, manually or by a combination of both. Feedback control (described herein) enables sphincter treatment apparatus


10


to be positioned and retained in the esophagus during treatment with minimal attention by the physician. Electrodes


88


can be multiplexed in order to treat the entire targeted treatment site


12


or only a portion thereof. Feedback can be included and is achieved by the use of one or more of the following methods: (i) visualization, (ii) impedance measurement, (iii) ultrasonography, (iv) temperature measurement; and, (v) sphincter contractile force measurement via manometry. The feedback mechanism permits the selected on-off switching of different electrodes


88


in a desired pattern, which can be sequential from one electrode


88


to an adjacent electrode


88


, or can jump around between non-adjacent electrodes


88


. Individual electrodes


88


are multiplexed and volumetrically controlled by a controller.




The area and magnitude of cell injury in the LES or sphincter


16


can vary. However, it is desirable to deliver sufficient energy to the targeted treatment site


12


to be able to achieve tissue temperatures in the range of 55-95° C. and produce lesions


14


at depths ranging from 1-4 mms from the interior surface of the LES or sphincter wall


26


. Typical energies delivered to the esophageal wall include, but are not limited to, a range between 100 and 50,000 joules per electrode


88


. It is also desirable to deliver sufficient energy such that the resulting lesions


14


have a sufficient magnitude and area of cell injury to cause an infiltration of lesion


14


by fibroblasts


110


, myofibroblasts


112


, macrophages


114


and other cells involved in the tissue healing process (refer to FIG.


21


). As shown in

FIG. 22

, these cells cause a contraction of tissue around lesion


14


, decreasing its volume and, or altering the biomechanical properties at lesion


14


so as to result in a tightening of LES or sphincter


16


. These changes are reflected in transformed lesion


14


′ shown in FIG.


19


B. The diameter of lesions


14


can vary between 0.1 to 4 mms. It is preferable that lesions


14


are less than 4 mms in diameter in order to reduce the risk of thermal damage to the mucosal layer. In one embodiment, a 2 mm diameter lesion


14


centered in the wall of the smooth muscle provides a 1 mm buffer zone to prevent damage to the mucosa, submucosa and adventitia, while still allowing for cell infiltration and subsequent sphincter tightening on approximately 50% of the thickness of the wall of the smooth muscle (refer to FIG.


23


).




From a diagnostic standpoint, it is desirable to image the interior surface and wall of the LES or other sphincter


16


, including the size and position of created lesions


14


. It is desirable to create a map of these structures which can input to a controller and used to direct the delivery of energy to the treatment site. Referring to

FIG. 24

, this can be accomplished through the use of ultrasonography (a known procedure) which involves the use of an ultrasound power source


116


coupled to one or more ultrasound transducers


118


that are positioned on expansion device


20


or basket assembly


50


. An output is associated with ultrasound power source


116


.




Each ultrasound transducer


118


can include a piezoelectric crystal


120


mounted on a backing material


122


that is in turn, attached to expansion device


20


or basket assembly


50


. An ultrasound lens


124


, fabricated on an electrically insulating material


126


, is mounted over piezoelectric crystal


120


. Piezoelectric crystal


120


is connected by electrical leads


128


to ultrasound power source


116


. Each ultrasound transducer


118


transmits ultrasound energy into adjacent tissue. Ultrasound transducers


118


can be in the form of an imaging probe such as Model 21362, manufactured and sold by Hewlett Packard Company, Palo Alto, Calif. In one embodiment, two ultrasound transducers


118


are positioned on opposite sides of expansion device


20


or basket assembly


50


to create an image depicting the size and position of lesion


14


in selected sphincter


16


.




It is desirable that lesions


14


are predominantly located in the smooth muscle layer of selected sphincter


16


at the depths ranging from 1 to 4 mms from the interior surface of sphincter wall


26


. However, lesions


14


can vary both in number and position within sphincter wall


26


. It may be desirable to produce a pattern of multiple lesions


14


within the sphincter smooth muscle tissue in order to obtain a selected degree of tightening of the LES or other sphincter


16


. Typical lesion patterns shown in

FIGS. 25A-D

include, but are not limited to, (i) a concentric circle of lesions


14


all at fixed depth in the smooth muscle layer evenly spaced along the radial axis of sphincter


16


, (ii) a wavy or folded circle of lesions


14


at varying depths in the smooth muscle layer evenly spaced along the radial axis of sphincter


16


, (iii) lesions


14


randomly distributed at varying depths in the smooth muscle, but evenly spaced in a radial direction; and, (iv) an eccentric pattern of lesions


14


in one or more radial locations in the smooth muscle wall. Accordingly, the depth of RF and thermal energy penetration sphincter


16


is controlled and selectable. The selective application of energy to sphincter


16


may be the even penetration of RF energy to the entire targeted treatment site


12


, a portion of it, or applying different amounts of RF energy to different sites depending on the condition of sphincter


16


. If desired, the area of cell injury can be substantially the same for every treatment event.




Referring to

FIG. 26

, it may be desirable to cool all or a portion of the area near the electrode-tissue interface


130


before, during or after the delivery of energy in order to reduce the degree and area of cell injury. Specifically, the use of cooling preserves the mucosal layers of sphincter wall


26


and protects, or otherwise reduces the degree of cell damage to cooled zone


132


in the vicinity of lesion


14


. Referring now to

FIG. 27

, this can be accomplished through the use of cooling solution


70


that is delivered by apertures


64


which is in fluid communication with shaft lumen


36


that is, in turn, in fluid communication with fluid reservoir


134


and a control unit


136


, whose operation is described herein, that controls the delivery of the fluid.




Similarly, it may also be desirable to cool all or a portion of the electrode


88


. The rapid delivery of heat through electrode


88


, may result in the build up of charred biological matter on electrode


88


(from contact with tissue and fluids e.g., blood) that impedes the flow of both thermal and electrical energy from electrode


88


to adjacent tissue and causes an electrical impedance rise beyond a cutoff value set on RF power source


24


. A similar situation may result from the desiccation of tissue adjacent to electrode


88


. Cooling of the electrode


88


can be accomplished by cooling solution


70


that is delivered by apertures


64


as described previously. Referring now to

FIG. 28

, electrode


88


may also be cooled via a fluid channel


138


in electrode


88


that is in fluid communication with fluid reservoir


134


and control unit


136


.




As shown in

FIG. 29

, one or more sensors


140


may be positioned adjacent to or on electrode


88


for sensing the temperature of sphincter tissue at treatment site


12


. More specifically, sensors


140


permit accurate determination of the surface temperature of sphincter wall


26


at electrode-tissue interface


130


. This information can be used to regulate both the delivery of energy and cooling solution


70


to the interior surface of sphincter wall


26


. In various embodiments, sensors


140


can be positioned at any position on expansion device


20


or basket assembly


50


. Suitable sensors that may be used for sensor


140


include: thermocouples, fiber optics, resistive wires, thermocouple IR detectors, and the like. Suitable thermocouples for sensor


140


include: T type with copper constantene, J type, E type and K types as are well known those skilled in the art.




Temperature data from sensors


140


are fed back to control unit


136


and through an algorithm which is stored within a microprocessor memory of control unit


136


. Instructions are sent to an electronically controlled micropump (not shown) to deliver fluid through the fluid lines at the appropriate flow rate and duration to provide control temperature at the electrode-tissue interface


130


(refer to FIG.


27


).




The reservoir of control unit


136


may have the ability to control the temperature of the cooling solution


70


by either cooling the fluid or heating the fluid. Alternatively, a fluid reservoir


134


of sufficient size may be used in which the cooling solution


70


is introduced at a temperature at or near that of the normal body temperature. Using a thermally insulated reservoir


142


, adequate control of the tissue temperature may be accomplished without need of refrigeration or heating of the cooling solution


70


. Cooling solution


70


flow is controlled by control unit


136


or another feedback control system (described herein) to provide temperature control at the electrode-tissue interface


130


.




A second diagnostic phase may be included after the treatment is completed. This provides an indication of LES tightening treatment success, and whether or not a second phase of treatment, to all or only a portion of the esophagus, now or at some later time, should be conducted. The second diagnostic phase is accomplished through one or more of the following methods: (i) visualization, (ii) measuring impedance, (iii) ultrasonography, (iv) temperature measurement, or (v) measurement of LES tension and contractile force via manometry.




In one embodiment, sphincter treatment apparatus


10


is coupled to an open or closed loop feedback system. Referring now to

FIG. 30

, an open or closed loop feedback system couples sensor


346


to energy source


392


. In this embodiment, electrode


314


is one or more RF electrodes


314


.




The temperature of the tissue, or of RF electrode


314


is monitored, and the output power of energy source


392


adjusted accordingly. The physician can, if desired, override the closed or open loop system. A microprocessor


394


can be included and incorporated in the closed or open loop system to switch power on and off, as well as modulate the power. The closed loop system utilizes microprocessor


394


to serve as a controller, monitor the temperature, adjust the RF power, analyze the result, refeed the result, and then modulate the power.




With the use of sensor


346


and the feedback control system a tissue adjacent to RF electrode


314


can be maintained at a desired temperature for a selected period of time without causing a shut down of the power circuit to electrode


314


due to the development of excessive electrical impedance at electrode


314


or adjacent tissue as is discussed herein. Each RF electrode


314


is connected to resources which generate an independent output. The output maintains a selected energy at RF electrode


314


for a selected length of time.




Current delivered through RF electrode


314


is measured by current sensor


396


. Voltage is measured by voltage sensor


398


. Impedance and power are then calculated at power and impedance calculation device


400


. These values can then be displayed at user interface and display


402


. Signals representative of power and impedance values are received by a controller


404


.




A control signal is generated by controller


404


that is proportional to the difference between an actual measured value, and a desired value. The control signal is used by power circuits


406


to adjust the power output in an appropriate amount in order to maintain the desired power delivered at respective RF electrodes


314


.




In a similar manner, temperatures detected at sensor


346


provide feedback for maintaining a selected power. Temperature at sensor


346


is used as a safety means to interrupt the delivery of energy when maximum pre-set temperatures are exceeded. The actual temperatures are measured at temperature measurement device


408


, and the temperatures are displayed at user interface and display


402


. A control signal is generated by controller


404


that is proportional to the difference between an actual measured temperature and a desired temperature. The control signal is used by power circuits


406


to adjust the power output in an appropriate amount in order to maintain the desired temperature delivered at the sensor


346


. A multiplexer can be included to measure current, voltage and temperature, at the sensor


346


, and energy can be delivered to RF electrode


314


in monopolar or bipolar fashion.




Controller


404


can be a digital or analog controller, or a computer with software. When controller


404


is a computer it can include a CPU coupled through a system bus. This system can include a keyboard, a disk drive, or other non-volatile memory systems, a display, and other peripherals, as are known in the art. Also coupled to the bus is a program memory and a data memory.




User interface and display


402


includes operator controls and a display. Controller


404


can be coupled to imaging systems including, but not limited to, ultrasound, CT scanners, X-ray, MRI, mammographic X-ray and the like. Further, direct visualization and tactile imaging can be utilized.




The output of current sensor


396


and voltage sensor


398


are used by controller


404


to maintain a selected power level at RF electrode


314


. The amount of RF energy delivered controls the amount of power. A profile of the power delivered to electrode


314


can be incorporated in controller


404


and a preset amount of energy to be delivered may also be profiled.




Circuitry, software and feedback to controller


404


result in process control, the maintenance of the selected power setting which is independent of changes in voltage or current, and is used to change the following process variables: (i) the selected power setting, (ii) the duty cycle (e.g., on-off time), (iii) bipolar or monopolar energy delivery; and, (iv) fluid delivery, including flow rate and pressure. These process variables are controlled and varied, while maintaining the desired delivery of power independent of changes in voltage or current, based on temperatures monitored at sensor


346


.




Referring now to

FIG. 31

, current sensor


396


and voltage sensor


398


are connected to the input of an analog amplifier


410


. Analog amplifier


410


can be a conventional differential amplifier circuit for use with sensor


346


. The output of analog amplifier


410


is sequentially connected by an analog multiplexer


412


to the input of A/D converter


414


. The output of analog amplifier


410


is a voltage which represents the respective sensed temperatures. Digitized amplifier output voltages are supplied by A/D converter


414


to microprocessor


394


. Microprocessor


394


may be a type 68HCII available from Motorola. However, it will be appreciated that any suitable microprocessor or general purpose digital or analog computer can be used to calculate impedance or temperature.




Microprocessor


394


sequentially receives and stores digital representations of impedance and temperature. Each digital value received by microprocessor


394


corresponds to different temperatures and impedances.




Calculated power and impedance values can be indicated on user interface and display


402


. Alternatively, or in addition to the numerical indication of power or impedance, calculated impedance and power values can be compared by microprocessor


394


to power and impedance limits. When the values exceed predetermined power or impedance values, a warning can be given on user interface and display


402


, and additionally, the delivery of RF energy can be reduced, modified or interrupted. A control signal from microprocessor


394


can modify the power level supplied by energy source


392


.





FIG. 32

illustrates a block diagram of a temperature and impedance feedback system that can be used to control the delivery of energy to tissue site


416


by energy source


392


and the delivery of cooling solution


70


to electrode


314


and/or tissue site


416


by flow regulator


418


. Energy is delivered to RF electrode


314


by energy source


392


, and applied to tissue site


416


. A monitor


420


ascertains tissue impedance, based on the energy delivered to tissue, and compares the measured impedance value to a set value. If the measured impedance exceeds the set value, a disabling signal


422


is transmitted to energy source


392


, ceasing further delivery of energy to RF electrode


314


. If measured impedance is within acceptable limits, energy continues to be applied to the tissue.




The control of cooling solution


70


to electrode


314


and/or tissue site


416


is done in the following manner. During the application of energy, temperature measurement device


408


measures the temperature of tissue site


416


and/or RF electrode


314


. A comparator


424


receives a signal representative of the measured temperature and compares this value to a pre-set signal representative of the desired temperature. If the tissue temperature is too high, comparator


424


sends a signal to a flow regulator


418


(connected to an electronically controlled micropump, not shown) representing a need for an increased cooling solution flow rate. If the measured temperature has not exceeded the desired temperature, comparator


424


sends a signal to flow regulator


418


to maintain the cooling solution flow rate at its existing level.




The foregoing description of a preferred embodiment of the invention has been presented for purposes of illustration and description. It is not intended to be exhaustive or to limit the invention to the precise forms disclosed. Obviously, many modifications and variations will be apparent to practitioners skilled in this art. It is intended that the scope of the invention be defined by the following claims and their equivalents.



Claims
  • 1. A method of treating tissue regions at or near the lower esophageal sphincter comprising the steps ofproviding an expandable basket structure with a coupled first, a second and a third arm, the expandable basket structure further including a first energy delivery device coupled to the first arm, wherein the basket structure has a non-deployed state and a deployed state, introducing the basket structure in the non-deployed state through an esophagus to a first tissue region comprising the cardia of the stomach, expanding the structure to the deployed state in the first tissue region, advancing the first energy delivery device from the basket structure to pierce an interior of the first tissue region, delivering sufficient energy from the first energy delivery device to create a lesion in the interior of the first region, retracting the first energy delivery device from the first tissue region, collapsing the structure to the non-deployed state, moving the structure in the non-deployed state from the first tissue region to a second tissue region comprising the lower esophageal sphincter, advancing the first energy delivery device from the basket structure to pierce an interior of the second tissue region, delivering sufficient energy from the first energy delivery device to create a lesion in the interior of the second tissue region, collapsing the structure to the non-deployed state, and removing the basket structure from the esophagus, whereby a pattern of lesions is formed in the first and second tissue regions to create a desired tissue effect.
  • 2. A method according to claim 1wherein the expandable basket further includes a second and a third energy delivery device each coupled to one of the second and third arms, and wherein during the advancing steps, the first, second, and third energy delivery devices pierce an interior of the respective first and second tissue regions to form an array of spaced apart lesions.
  • 3. A method according to claim 1wherein the desired tissue effect includes a reduction in a duration of lower esophageal sphincter relaxation.
  • 4. A method according to claim 1wherein the desired tissue effect includes a reduction in a frequency of reflux of stomach contents into the esophagus.
  • 5. A method according to claim 1wherein the desired tissue effect includes a reduction of a frequency of a symptom of reflux of stomach contents into the esophagus.
  • 6. A method according to of claim 1wherein the desired tissue effect includes a reduction of an incidence of a sequela of reflux of stomach contents into the esophagus.
  • 7. A method according to claim 1wherein the desired tissue effect includes a tightening of the lower esophageal sphincter.
  • 8. A method according to claim 1further comprising a step of introducing a fluid to at least one of the first and second tissue regions.
  • 9. A method according to claim 1wherein the first energy delivery device comprises an RF needle electrode.
  • 10. A method according to claim 1wherein the desired tissue effect includes blocking of an electrical conduction pathway in at least one of the esophagus, the lower esophageal sphincter, and the cardia.
  • 11. A method according to claim 1wherein the desired tissue effect includes ablating an electrical pathway in at least one of the esophagus, the lower esophageal sphincter, and the cardia.
  • 12. A method according to claim 1wherein the desired tissue effect includes ablating an electrical foci in at least one of the esophagus, the lower esophageal sphincter, and the cardia.
  • 13. A method according to claim 1wherein the desired tissue effect includes inducing necrosis of an electrical conduction pathway in at least one of the esophagus, the lower esophageal sphincter, and the cardia.
Parent Case Info

This application is a continuation of U.S. patent application Ser. No. 09/360,599, filed Jul. 26, 1999, now abandoned, which is a continuation of U.S. patent application Ser. No. 09/026,296, filed Feb. 19, 1998 (now U.S. Pat. No. 6,009,877).

US Referenced Citations (151)
Number Name Date Kind
1798902 Raney Mar 1931 A
3517128 Hines Jun 1970 A
3901241 Allen, Jr. Aug 1975 A
4011872 Komiya Mar 1977 A
4196724 Wirt et al. Apr 1980 A
4411266 Cosman Oct 1983 A
4423812 Sato Jan 1984 A
4532924 Auth et al. Aug 1985 A
4565200 Cosman Jan 1986 A
4705041 Kim Nov 1987 A
4901737 Toone Feb 1990 A
4906203 Margrave et al. Mar 1990 A
4907589 Cosman Mar 1990 A
4943290 Rexroth et al. Jul 1990 A
4947842 Marchosky et al. Aug 1990 A
4955377 Lennox et al. Sep 1990 A
4966597 Cosman Oct 1990 A
4976711 Parins et al. Dec 1990 A
5019075 Spears et al. May 1991 A
5035696 Rydell Jul 1991 A
5046512 Murchie Sep 1991 A
5047028 Qian Sep 1991 A
5057107 Parins et al. Oct 1991 A
5078717 Parins et al. Jan 1992 A
5083565 Parins Jan 1992 A
5084044 Quint Jan 1992 A
5088979 Filipi et al. Feb 1992 A
5094233 Brennan Mar 1992 A
5100423 Fearnot Mar 1992 A
5106360 Ishiwara et al. Apr 1992 A
5122137 Lennox Jun 1992 A
5125928 Parins et al. Jun 1992 A
5156151 Imran Oct 1992 A
5190541 Abele et al. Mar 1993 A
5197963 Parins Mar 1993 A
5197964 Parins Mar 1993 A
5201732 Parins et al. Apr 1993 A
5205287 Erbel et al. Apr 1993 A
5215103 Desai Jun 1993 A
5232444 Just et al. Aug 1993 A
5236413 Feiring Aug 1993 A
5242441 Avitall Sep 1993 A
5254126 Filipi et al. Oct 1993 A
5256138 Burek et al. Oct 1993 A
5257451 Edwards et al. Nov 1993 A
5263493 Avitall Nov 1993 A
5275162 Edwards et al. Jan 1994 A
5275608 Forman et al. Jan 1994 A
5275610 Eberbach Jan 1994 A
5277201 Stern Jan 1994 A
5281216 Klicek Jan 1994 A
5281217 Edwards et al. Jan 1994 A
5281218 Imran Jan 1994 A
5290286 Parins Mar 1994 A
5292321 Lee Mar 1994 A
5293869 Edwards et al. Mar 1994 A
5305696 Mendenhall Apr 1994 A
5309910 Edwards et al. May 1994 A
5313943 Houser et al. May 1994 A
5314466 Stern et al. May 1994 A
5316020 Truffer May 1994 A
5324284 Imran Jun 1994 A
5328467 Edwards et al. Jul 1994 A
5334196 Scott et al. Aug 1994 A
5336222 Durgin, Jr. et al. Aug 1994 A
5345936 Pomeranz et al. Sep 1994 A
5348554 Imran et al. Sep 1994 A
5363861 Edwards et al. Nov 1994 A
5365926 Desai Nov 1994 A
5365945 Halstrom Nov 1994 A
5366490 Edwards et al. Nov 1994 A
5368557 Nita et al. Nov 1994 A
5368592 Stern et al. Nov 1994 A
5370675 Edwards et al. Dec 1994 A
5370678 Edwards et al. Dec 1994 A
5383876 Nardella Jan 1995 A
5383917 Desai et al. Jan 1995 A
5385544 Edwards et al. Jan 1995 A
5397339 Desai Mar 1995 A
5398683 Edwards et al. Mar 1995 A
5401272 Perkins Mar 1995 A
5403311 Abele et al. Apr 1995 A
5409453 Lundquist et al. Apr 1995 A
5409483 Campbell et al. Apr 1995 A
5415657 Taymor-Luria May 1995 A
5421819 Edwards et al. Jun 1995 A
5423808 Edwards et al. Jun 1995 A
5423811 Imran et al. Jun 1995 A
5423812 Ellman et al. Jun 1995 A
5433739 Sluijter et al. Jul 1995 A
5435805 Edwards Jul 1995 A
5441499 Fritzsch Aug 1995 A
5443470 Stern et al. Aug 1995 A
5454782 Perkins Oct 1995 A
5456662 Edwards et al. Oct 1995 A
5456682 Edwards et al. Oct 1995 A
5458596 Lax et al. Oct 1995 A
5458597 Edwards et al. Oct 1995 A
5465717 Imran et al. Nov 1995 A
5470308 Edwards et al. Nov 1995 A
5471982 Edwards et al. Dec 1995 A
5472441 Edwards et al. Dec 1995 A
5484400 Edwards et al. Jan 1996 A
5486161 Lax et al. Jan 1996 A
5490984 Freed Feb 1996 A
5496271 Burton et al. Mar 1996 A
5496311 Abele et al. Mar 1996 A
5500012 Brucker et al. Mar 1996 A
5505728 Ellman et al. Apr 1996 A
5505730 Edwards Apr 1996 A
5507743 Edwards et al. Apr 1996 A
5509419 Edwards et al. Apr 1996 A
5514130 Baker May 1996 A
5514131 Edwards et al. May 1996 A
5520684 Imran May 1996 A
5531676 Edwards et al. Jul 1996 A
5531677 Lundquist et al. Jul 1996 A
5536240 Edwards et al. Jul 1996 A
5536267 Edwards et al. Jul 1996 A
5540655 Edwards et al. Jul 1996 A
5549644 Lundquist et al. Aug 1996 A
5554110 Edwards et al. Sep 1996 A
5556377 Rosen et al. Sep 1996 A
5558672 Edwards et al. Sep 1996 A
5558673 Edwards et al. Sep 1996 A
5562720 Stern et al. Oct 1996 A
5571116 Bolanos et al. Nov 1996 A
5578007 Imran Nov 1996 A
5588432 Crowley Dec 1996 A
5588960 Edwards et al. Dec 1996 A
5599345 Edwards et al. Feb 1997 A
5609151 Mulier et al. Mar 1997 A
5624439 Edwards et al. Apr 1997 A
5672153 Lax et al. Sep 1997 A
5676674 Bolanos et al. Oct 1997 A
5688266 Edwards et al. Nov 1997 A
5688490 Tournier et al. Nov 1997 A
5702438 Avitall Dec 1997 A
5709224 Behl et al. Jan 1998 A
5732698 Swanson et al. Mar 1998 A
5738096 Ben-Haim Apr 1998 A
5810807 Ganz et al. Sep 1998 A
5830213 Panescu et al. Nov 1998 A
5836874 Swanson et al. Nov 1998 A
5860974 Abele Jan 1999 A
5871483 Jackson et al. Feb 1999 A
5957920 Baker Sep 1999 A
6009877 Edwards Jan 2000 A
6044846 Edwards Apr 2000 A
6073052 Zelickson et al. Jun 2000 A
6092528 Edwards Jul 2000 A
Foreign Referenced Citations (21)
Number Date Country
43 03 882 Feb 1995 DE
38 38 840 Feb 1997 DE
0 139 607 May 1985 EP
0 608 609 Aug 1994 EP
9101773 Feb 1991 WO
9210142 Jun 1992 WO
9308755 May 1993 WO
9410925 May 1994 WO
9421165 Sep 1994 WO
9421178 Sep 1994 WO
9422366 Oct 1994 WO
9426178 Nov 1994 WO
9518575 Jul 1995 WO
9519142 Jul 1995 WO
9525472 Sep 1995 WO
9600042 Jan 1996 WO
9616606 Jun 1996 WO
9629946 Oct 1996 WO
9706857 Feb 1997 WO
9732532 Sep 1997 WO
9743971 Nov 1997 WO
Non-Patent Literature Citations (12)
Entry
Hinder, R.A. et al., “The Technique of Labaroscopic Nissen Fundoplication.” Surgical Laparoscopy and Endoscopy. 1992. 2(3): 265-272.
Karlstrom, L.H. et al., “Ectopic jejunal pacemakers and enterogastric reflux after Roux gastrectomy: Effect of intestinal pacing.” Surgery 1989. 106(3): 486-495.
Kelly, KA. et al., “Doudenal-gastric reflux and slowed gastric emptying by electrical pacing of the canine duodenal pacesetter potential.” Gastroenterology. 1977. 72(3): 429-33.
Reynolds, J.C. “Influence of pathophysiology, severity, and cost on the medical management of gastroesophageal reflux disease.” Am J Health-Syst Pharm. 53 ( 22 Suppl 3): S5-12.
Urschel, J.D. “Complications of Antireflux Surgery.” Am J Surg. 1993. 166(1): 68-70.
Kaneko, et al., Physiological Laryngeal Pacemaker, May 1985, Trans Am Soc. Artif. Intern Organs, vol. XXXI, pp. 293-296.
Mugica et al. Direct Diaphragm Stimulation, Jan. 1987 PACE, vol. 10, pp. 252-256.
Mugica et al., Neurostimulation: An Overview, Chapter 21, Preliminary Test of a Muscular Diaphragm pacing System on Human Patients. 1985. pgs3. 263-279.
Rice et al., Endoscopic Paranasal Sinus Surgery, Chapter 5, Functional Endoscopic Paranasal Sinus Surgery, The Technique of Messerklinger, Raven Press, 1988, pp. 75-104.
Rice et al., Endoscopic Paranasal Sinus Surgery, Chapter 6, Total Endoscopic Sphenoethmoidectomy, The Technique of Wigand, Raven Press, 1988, pp. 105-125.
Castell, D.O. “Gastroesophageal Reflux Disease: Current Strategies for Patient Management.” Arch Farm Med. 5(4): 221-7.
Dallemagne, B. et al., “Laparoscopic Nissen Fundoplication: Preliminary.” Surgical Laparoscopy & Endoscopy. 1997 1(3): 138-43.
Continuations (2)
Number Date Country
Parent 09/360599 Jul 1999 US
Child 09/973467 US
Parent 09/026296 Feb 1998 US
Child 09/360599 US